Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Thursday, September 5, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Talphera, Inc. has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, to be held from September 9-11, 2024, in New York City. The company will engage in one-on-one meetings and make a presentation available on-demand. Talphera focuses on developing innovative therapies, notably Niyad™, an anticoagulant currently under investigation and designated as a Breakthrough Device by the FDA, underscoring its potential importance in medical settings.
Price reaction · baseline $0.9563 (2024-09-04 close) · hit after-hours · clean, no other TLPH news in the window
day 0 close · peak
+5.6%
day 1
+3.5%
day 3
-3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera will be participating in the H.C. Wainwright 26th Annual Global Investment Conference.
  • The presentation will be available on-demand, increasing accessibility.
  • Talphera's lead product candidate, Niyad™, has received Breakthrough Device Designation from the FDA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+222%
120-day peak, hindsight
Typical move
22.4%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
sufentanil
Phase 3 · Moderate-to-severe Acute Pain

Full Press Release Details

SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.
The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

What is Talphera, Inc. focused on?

Talphera, Inc. specializes in developing and commercializing innovative therapies for medically supervised settings.

What notable product is Talphera developing?

Talphera's lead product candidate is Niyad™, a formulation of nafamostat.

When is the H.C. Wainwright Conference taking place?

The conference is scheduled for September 9-11, 2024, in New York City.

How can I access the conference presentation?

The presentation will be available on-demand starting September 9 at 7:00 AM ET.

What designation has Niyad™ received from the FDA?

Niyad™ has received Breakthrough Device Designation status from the FDA.

ShareAdd on Google
Tags: TLPH Viatris Investor Conferences Healthcare Talphera H.C. Wainwright Niyad FDA Breakthrough Device
Last updated: Sep 5, 2024

Biotech snapshot

Cash runway
$17M liquidity · $1M/mo burn
~13 mo
Low dilution risk
Lead asset
sufentanilPhase 3
Moderate-to-severe Acute Pain →

Catalyst track record

+222%
best trade around TLPH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TLPH.

See every catalyst's timing & PoA →